Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
912.1 INR | +1.24% | +0.48% | +0.23% |
May. 22 | Eris Lifesciences Posts Gains in Fiscal Q4 Consolidated Net Profit | MT |
May. 21 | Eris Lifesciences Gets Board Nod to Raise Up to INR12.50 Billion Via Bond Sale | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With an expected P/E ratio at 29.96 and 30.54 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.26% | 1.47B | D+ | ||
+38.59% | 727B | C+ | ||
-7.89% | 347B | C+ | ||
+15.66% | 319B | B- | ||
+0.24% | 274B | C+ | ||
+13.19% | 238B | B+ | ||
+7.01% | 204B | B- | ||
-6.50% | 203B | A+ | ||
+4.23% | 161B | C+ | ||
-1.70% | 160B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ERIS Stock
- Ratings Eris Lifesciences Limited